GI & Endoscopy

Ninety percent of Takeda's shareholders voted down a proposal that would've required all acquisitions be put to a vote at the company's annual meeting June 28, Reuters reports.

Neither atezolizumab alone or with cobimetinib improved overall survival, objective responses or progression-free survival in patients with metastatic colon cancer compared to the standard approach of using regorafenib, according to data presented at the ESMO World Congress on Gastrointestinal Cancer…

Waco (Texas) Gastroenterology Associates is expanding in response to increased demand, according to Waco Today.

The struggle between Jackson-based University of Mississippi Medical Center and Blue Cross and Blue Shield of Mississippi to agree upon a new contract could leave patients footing the $5,135 bill for colonoscopy, according to the Clarion Ledger.

Pentax Medical published several lectures from a symposium on endoscopic infection control, according to Zenopa.

Here are four updates on GI companies from the past week:

Clarivate Analytics doled out its impact score rankings, affirming Gastroenterology's spot as the No. 1 premier journal in gastroenterology.

Using EndoGastric Solution's EsophyX Z device to perform the transoral incisionless fundoplication 2.0 procedure in achalasia patients who have undergone peroral endoscopic myotomy is a safe and effective treatment, according to a study in Endoscopy International Open.

Exact Sciences and the American Association of Nurse Practitioners released the results of their HealthyWomen's National Colorectal Cancer Screening Knowledge and Patient Patterns Survey.

U.S. News & World Report released its 2018 to 2019 rankings of the best children's hospitals for pediatric gastroenterology and GI surgery.